IL161036A0 - Methods and compositions to determine the chemosensitizing dose of suramin used in combination therapy - Google Patents

Methods and compositions to determine the chemosensitizing dose of suramin used in combination therapy

Info

Publication number
IL161036A0
IL161036A0 IL16103602A IL16103602A IL161036A0 IL 161036 A0 IL161036 A0 IL 161036A0 IL 16103602 A IL16103602 A IL 16103602A IL 16103602 A IL16103602 A IL 16103602A IL 161036 A0 IL161036 A0 IL 161036A0
Authority
IL
Israel
Prior art keywords
chemosensitizing
dose
compositions
methods
combination therapy
Prior art date
Application number
IL16103602A
Other languages
English (en)
Inventor
Jessie L S Au
Guillaume M Wientjes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of IL161036A0 publication Critical patent/IL161036A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL16103602A 2001-09-24 2002-09-24 Methods and compositions to determine the chemosensitizing dose of suramin used in combination therapy IL161036A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32470401P 2001-09-24 2001-09-24
PCT/US2002/030210 WO2003026574A2 (en) 2001-09-24 2002-09-24 Methods and compositions to determine the chemosensitizing dose of suramin used in combination therapy

Publications (1)

Publication Number Publication Date
IL161036A0 true IL161036A0 (en) 2004-08-31

Family

ID=23264730

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16103602A IL161036A0 (en) 2001-09-24 2002-09-24 Methods and compositions to determine the chemosensitizing dose of suramin used in combination therapy

Country Status (9)

Country Link
US (2) US20040180955A1 (OSRAM)
EP (1) EP1429713A4 (OSRAM)
JP (1) JP2005508322A (OSRAM)
KR (1) KR20040062546A (OSRAM)
CN (1) CN100441176C (OSRAM)
AU (1) AU2002330088B2 (OSRAM)
CA (1) CA2461227C (OSRAM)
IL (1) IL161036A0 (OSRAM)
WO (1) WO2003026574A2 (OSRAM)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6905669B2 (en) 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
US6982253B2 (en) 2002-06-05 2006-01-03 Supergen, Inc. Liquid formulation of decitabine and use of the same
US20050043233A1 (en) 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
US7250416B2 (en) 2005-03-11 2007-07-31 Supergen, Inc. Azacytosine analogs and derivatives
US7700567B2 (en) 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
WO2007065016A2 (en) * 2005-12-02 2007-06-07 Au Jessie L S Methods and compositions to improve activity and reduce toxicity of stents
JP2010535232A (ja) * 2007-07-30 2010-11-18 アルディア バイオサイエンス，インク． Ｍｅｋの阻害剤としての多形体を含む、ｎ−（アリールアミノ）スルホンアミドの誘導体、および組成物、使用方法、ならびにその調製方法
EP2750768B1 (en) 2011-08-30 2018-10-03 Astex Pharmaceuticals, Inc. Decitabine derivative formulations
CN104398517A (zh) * 2014-11-28 2015-03-11 四川大学 乙胺嘧啶的新用途及治疗肿瘤的药物组合物
KR20180024010A (ko) 2015-07-02 2018-03-07 오쓰까 세이야꾸 가부시키가이샤 동결건조된 약제학적 조성물
TW201718598A (zh) * 2015-08-27 2017-06-01 美國禮來大藥廠 Ｅｚｈ２抑制劑
EP3661522A2 (en) 2017-08-03 2020-06-10 Otsuka Pharmaceutical Co., Ltd. Drug compound and purification methods thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5597830A (en) * 1994-12-20 1997-01-28 Warner-Lambert Company Combination chemotherapy
ATE302599T1 (de) * 1996-05-24 2005-09-15 Angiotech Pharm Inc Zubereitungen und verfahren zur behandlung oder prävention von krankheiten der körperpassagewege
JP2001500899A (ja) * 1997-03-11 2001-01-23 レ ラボラトワール エテルナ インコーポレイティド 高い効能及び少ない副作用を供与する軟骨エキスと抗新形成剤との組合せを含んで成る抗腫瘍療法
US6506783B1 (en) * 1997-05-16 2003-01-14 The Procter & Gamble Company Cancer treatments and pharmaceutical compositions therefor
US6599912B1 (en) * 1999-06-03 2003-07-29 Jessie L. -S. Au Methods and compositions for modulating cell proliferation and cell death
US6420378B1 (en) * 1999-10-15 2002-07-16 Supergen, Inc. Inhibition of abnormal cell proliferation with camptothecin and combinations including the same

Also Published As

Publication number Publication date
EP1429713A2 (en) 2004-06-23
JP2005508322A (ja) 2005-03-31
US8580857B2 (en) 2013-11-12
CA2461227C (en) 2012-05-15
US20040180955A1 (en) 2004-09-16
US20110142794A1 (en) 2011-06-16
CA2461227A1 (en) 2003-04-03
CN100441176C (zh) 2008-12-10
KR20040062546A (ko) 2004-07-07
EP1429713A4 (en) 2007-08-08
WO2003026574A3 (en) 2004-04-15
WO2003026574A2 (en) 2003-04-03
AU2002330088B2 (en) 2009-09-03
HK1074167A1 (zh) 2005-11-04
CN1589138A (zh) 2005-03-02

Similar Documents

Publication Publication Date Title
AU6118001A (en) Combination therapeutic compositions and methods of use
HUP0600780A2 (en) Compositions and methods for the therapy and diagnosis of her-2/neu-associated malignancies
AU6147401A (en) Compositions and methods for the treatment of cancer
AU3679801A (en) Optically-active nanoparticles for use in therapeutic and diagnostic methods
EP1210063A4 (en) COMPOSITIONS AND METHODS FOR IMPROVING THE ABSORPTION OF HYDROPHILIC THERAPEUTIC ACTIVE SUBSTANCES
AU4244200A (en) Multi-functional therapeutic compress and methods of using the same
PL366626A1 (en) Compositions and methods for the therapy and diagnosis of lung cancer
IL163876A0 (en) Therapeutic methods and compositions involving isovlav-3-ene and isoflavan structures
IL161036A0 (en) Methods and compositions to determine the chemosensitizing dose of suramin used in combination therapy
EE200300473A (et) Tsüano-asendatud dihüdropürimidiinühendid ja nende kasutamine haiguste raviks
EE200300474A (et) Tsüano-asendatud dihüdropürimidiinühendid ja nende kasutamine haiguste raviks
AU2003265620A8 (en) Cardiovascular therapy composition including transfer factor and therapeutic methods including use of the composition
HUP0401484A3 (en) Use of bibn4096 in combination with other antimigraine drugs for the treatment of migraine and pharmaceutical compositions containing the combination
GB0615918D0 (en) Composition and its therapeutic use
AU2002359618A1 (en) Medicinal compositions and therapeutic methods
IL160722A0 (en) Aryloxypropylamines as chemosensitizing agents in the treatment of cancer
GB0007217D0 (en) Materials and methods relating to the treatment of leukaemias
EP1583543A4 (en) METHOD AND THERAPEUTIC COMPOSITIONS IN THE TREATMENT OF ADVANCED CARCINOMA
AU2001285026A1 (en) Methods and compositions for use in the diagnosis and treatment of chronic immune disease
GB0205826D0 (en) Therapeutic compositions and methods
GB0108772D0 (en) Therapeutic methods and compositions for use therein
GB0129264D0 (en) Improvements in and relating to investigations of radioactivity
GB0128354D0 (en) Improvements in and relating to investigations of radioactivity
GB0130733D0 (en) Therapeutic compounds and their use in therapy
GB0203043D0 (en) Benzimidazloe compounds their preparation and their use in therapy